Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30677190 | 0.85 | GABRA1 (0.35) | GABRA1GABRB2 | |
| SCHEMBL8175165 | 0.83 | KDM4E (0.31) | — | |
| SCHEMBL8567643 | 0.77 | — | — | |
| SCHEMBL15680396 | 0.76 | GABRA1 (0.32) | GABRA1GABRB2 | |
| SCHEMBL20085793 | 0.76 | ADORA2A (0.41) | — | |
| SCHEMBL7766739 | 0.76 | SELE (0.38) | — | |
| SCHEMBL13971734 | 0.75 | GABRA1 (0.35) | GABRA1GABRB2 | |
| SCHEMBL10699821 | 0.74 | NOS3 (0.33) | — | |
| SCHEMBL2324216 | 0.74 | FEN1 (0.30) | — | |
| SCHEMBL1660309 | 0.74 | KDM4E (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109906224-B | Triazolopyridine compounds and uses thereof | 诺华股份有限公司 | 2022-02-25 | — | — | CN | disclosed |
| US-10689378-B2 | Triazolopyridine compounds and uses thereof | NOVARTIS AG (CH) | 2020-06-23 | — | — | US | disclosed |
| EP-3472161-B1 | TRIAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2020-03-25 | — | — | EP | disclosed |
| US-20190202828-A1 | TRIAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2019-07-04 | — | — | US | disclosed |
| EP-3472161-A1 | TRIAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | Novartis AG (CH) | 2019-04-24 | — | — | EP | disclosed |
| WO-2017221092-A1 | TRIAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2017-12-28 | — | — | WO | disclosed |
| WO-2000063176-A2 | DISUBSTITUTED PYRIDINES AND PYRIMIDINES AS HERBICIDES AND FUNGICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 2000-10-26 | — | — | WO | disclosed |
| EP-0470600-B1 | Naphthylalkylaminopyrimidine derivatives, process for their preparation and pesticides containing them | CIBA GEIGY AG (CH) | 1997-05-07 | — | — | EP | disclosed |
| US-5468751-A | Aminopyrimidine derivatives as microbicides, insecticides and acaricides | CIBA-GEIGY CORPORATION (US) | 1995-11-21 | — | — | US | disclosed |
| CN-1058776-A | Agricultural chemicals | CIBA GEIGY AG (CH) | 1992-02-19 | — | — | CN | disclosed |
| EP-0470600-A1 | Naphthylalkylaminopyrimidine derivatives, process for their preparation and pesticides containing them | CIBA-GEIGY AG (CH) | 1992-02-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190202828-A1 | TRIAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | EZH2, EED, BMI1 | GABRA1 1644/4885GABRB2 1863/4885 |
| US-10689378-B2 | Triazolopyridine compounds and uses thereof | EZH2, EED, BMI1 | GABRA1 1644/4885GABRB2 1863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.